Compare EXLS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXLS | BLCO |
|---|---|---|
| Founded | 1999 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.1B |
| IPO Year | 2004 | 2022 |
| Metric | EXLS | BLCO |
|---|---|---|
| Price | $35.26 | $17.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $46.80 | $18.45 |
| AVG Volume (30 Days) | ★ 1.8M | 380.8K |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $12.61 | $8.65 |
| Revenue Next Year | $10.55 | $5.59 |
| P/E Ratio | $81.28 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $24.85 | $13.77 |
| 52 Week High | $44.32 | $18.92 |
| Indicator | EXLS | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 58.93 |
| Support Level | $28.77 | $16.26 |
| Resistance Level | $36.27 | $17.78 |
| Average True Range (ATR) | 0.88 | 0.42 |
| MACD | -0.58 | 0.00 |
| Stochastic Oscillator | 0.96 | 48.20 |
ExlService Holdings Inc. is a data analytics and digital operations company that provides data and AI-led solutions and technology-enabled services to clients across industries. The company has four reportable segments. The Insurance segment provides services such as claims management, underwriting support, and analytics solutions. The Healthcare and Life Sciences segment offers data-driven solutions and services to healthcare payers, providers, and life sciences organizations. The Banking, Capital Markets and Diversified Industries segment delivers solutions across financial services and other industries. The International Growth Markets segment focuses on providing data, AI, and digital operations services to clients outside North America.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.